Overview

A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Nippon Kayaku Co., Ltd.
Nippon Kayaku Co.,Ltd.